Meningioma natural history: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
{{Meningioma}}
{{Meningioma}}
{{CMG}}
{{CMG}} {{AE}}{{HL}}


==Overview==
==Overview==
==Natural History==




==Complications==
==Complications==
*Cranial nerve disorder
 
*Raised intracranial pressure
*Cerebral Herniation


==Prognosis==
==Prognosis==
As a benign tumor, the prognosis of meningioma depends on the following:


:*The location the tumor


:*Whether or not the tumor can be removed by surgery
*The table below lists common prognostic factors for meningioma:
 
{| {{table}}
| align="center" style="background:#f0f0f0;"|'''Prognostic Factor'''
 
| align="center" style="background:#f0f0f0;"|'''Description'''
 
|-
 
| '''Stage'''||Advanced stages of multiple myeloma are associated with poor prognosis.<ref name="Canadian">Multiple myeloma. Canadian cancer society (2015)http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/prognosis-and-survival/?region=mb Accessed on September, 20th 2015</ref>
 
|-
 
| '''Kidney function'''||An elevated level of creatinine is associated with poor prognosis.<ref name="Canadian">Multiple myeloma. Canadian cancer society (2015)http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/prognosis-and-survival/?region=mb Accessed on September, 20th 2015</ref>
 
|-
 
| '''Labelling index'''||The labeling index indicates how fast the cancer cells are growing. A high plasma cell labeling index (PCLI) or proliferation (reproduction) rate is associated with poor prognosis.<ref name="Canadian">Multiple myeloma. Canadian cancer society (2015)http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/prognosis-and-survival/?region=mb Accessed on September, 20th 2015</ref>
 
|-
 
| '''Age'''||Older patients have worse prognosis than younger patients.<ref name="Canadian">Multiple myeloma. Canadian cancer society (2015)http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/prognosis-and-survival/?region=mb Accessed on September, 20th 2015</ref>
 
|-
 
| '''Chromosome changes'''||[[Cytogenetic]] analysis of multiple myeloma cells may be of [[prognosis|prognostic value]], with deletion of chromosome 13, non-hyperdiploidy and the balanced translocations t(4;14) and t(14;16) conferring a poorer prognosis.  The 11q13 and 6p21 cytogenetic abnormalities are associated with a better prognosis.<ref name="Canadian">Multiple myeloma. Canadian cancer society (2015)http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/prognosis-and-survival/?region=mb Accessed on September, 20th 2015</ref><ref name="wiki">Multiple myeloma. Wikipedia (2015)https://en.wikipedia.org/wiki/Multiple_myeloma#Prognosis Accessed on September, 20th 2015</ref>
 
|-
 
| '''Assocciated plasma cell disorder'''||The presence of [[plasma cell leukemia]] or soft tissue plasmacytoma is associated with a particularly poor prognosis among patients with multiple myeloma.<ref>Plasma cell neoplasm. Cancer.gov (2015)http://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq#link/_40_toc </ref>
 
|-
 
| '''Performance status'''||Performance status is ranked on a 0–4 scale. The lower the number, the healthier and more active the person is, and the better the prognosis. Performance status is important in multiple myeloma because people who are healthier can withstand more intensive treatment.<ref name="Canadian">Multiple myeloma. Canadian cancer society (2015)http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/prognosis-and-survival/?region=mb Accessed on September, 20th 2015</ref>
 
|-
 
| '''Beta-2-microglobulin'''||A higher level of beta-2-microglobulin is associated with poor prognosis.<ref name="Canadian">Multiple myeloma. Canadian cancer society (2015)http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/prognosis-and-survival/?region=mb Accessed on September, 20th 2015</ref>
 
|-
 
| '''Albumin level'''||A lower albumin level is associated with poor prognosis.<ref name="Canadian">Multiple myeloma. Canadian cancer society (2015)http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/prognosis-and-survival/?region=mb Accessed on September, 20th 2015</ref>
 
|-
 
| '''Lactate dehydrogenase level'''||A higher level of lactate dehydrogenase (LDH) is associated with poor prognosis.<ref name="Canadian">Multiple myeloma. Canadian cancer society (2015)http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/prognosis-and-survival/?region=mb Accessed on September, 20th 2015</ref>
 
|-
 
| '''Response to treatment'''||People whose cancer responds to treatment and goes into complete remission have a better prognosis than people whose cancer does not respond to the initial treatment.<ref name="Canadian">Multiple myeloma. Canadian cancer society (2015)http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/prognosis-and-survival/?region=mb Accessed on September, 20th 2015</ref>
|}
 
==References==
{{Reflist|2}}


:*Whether the tumor has recurred
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}


:*The magnitude of calcification of the tumor and its adherence to surrounding structures
[[Category:Disease]]
[[Category:Hematology]]
[[Category:Types of cancer]]


==References==
==References==

Revision as of 18:54, 25 September 2015

Meningioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Meningioma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Meningioma natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Meningioma natural history

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Meningioma natural history

CDC on Meningioma natural history

Meningioma natural history in the news

Blogs on Meningioma natural history

Directions to Hospitals Treating Meningioma

Risk calculators and risk factors for Meningioma natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]

Overview

Natural History

Complications

Prognosis

  • The table below lists common prognostic factors for meningioma:
Prognostic Factor Description
Stage Advanced stages of multiple myeloma are associated with poor prognosis.[1]
Kidney function An elevated level of creatinine is associated with poor prognosis.[1]
Labelling index The labeling index indicates how fast the cancer cells are growing. A high plasma cell labeling index (PCLI) or proliferation (reproduction) rate is associated with poor prognosis.[1]
Age Older patients have worse prognosis than younger patients.[1]
Chromosome changes Cytogenetic analysis of multiple myeloma cells may be of prognostic value, with deletion of chromosome 13, non-hyperdiploidy and the balanced translocations t(4;14) and t(14;16) conferring a poorer prognosis. The 11q13 and 6p21 cytogenetic abnormalities are associated with a better prognosis.[1][2]
Assocciated plasma cell disorder The presence of plasma cell leukemia or soft tissue plasmacytoma is associated with a particularly poor prognosis among patients with multiple myeloma.[3]
Performance status Performance status is ranked on a 0–4 scale. The lower the number, the healthier and more active the person is, and the better the prognosis. Performance status is important in multiple myeloma because people who are healthier can withstand more intensive treatment.[1]
Beta-2-microglobulin A higher level of beta-2-microglobulin is associated with poor prognosis.[1]
Albumin level A lower albumin level is associated with poor prognosis.[1]
Lactate dehydrogenase level A higher level of lactate dehydrogenase (LDH) is associated with poor prognosis.[1]
Response to treatment People whose cancer responds to treatment and goes into complete remission have a better prognosis than people whose cancer does not respond to the initial treatment.[1]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Multiple myeloma. Canadian cancer society (2015)http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/prognosis-and-survival/?region=mb Accessed on September, 20th 2015
  2. ↑ Multiple myeloma. Wikipedia (2015)https://en.wikipedia.org/wiki/Multiple_myeloma#Prognosis Accessed on September, 20th 2015
  3. ↑ Plasma cell neoplasm. Cancer.gov (2015)http://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq#link/_40_toc


Template:WikiDoc Sources

References


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Meningioma_natural_history&oldid=1163113"